Evidence for possible clinical benefit from mobilizing the CD70/CD27 pathway was provided by a recent clinical trial utilizing DCs expressing CD70, CD40L, and constitutively active TLR4 (TriMix-DC) in the treatment of metastatic melanoma patients. Here, CD70 is linked to metastatic melanoma.